{"id":5184,"date":"2024-04-09T13:46:32","date_gmt":"2024-04-09T11:46:32","guid":{"rendered":"https:\/\/www.id-solutions.fr\/2024\/04\/09\/liquid-biopsy-follow-up-a-new-era-for-women-treated-for-advanced-breast-cancer\/"},"modified":"2024-11-29T09:09:18","modified_gmt":"2024-11-29T08:09:18","slug":"liquid-biopsy-follow-up-a-new-era-for-women-treated-for-advanced-breast-cancer","status":"publish","type":"post","link":"https:\/\/www.id-solutions.fr\/en\/2024\/04\/09\/liquid-biopsy-follow-up-a-new-era-for-women-treated-for-advanced-breast-cancer\/","title":{"rendered":"Liquid biopsy follow-up"},"content":{"rendered":"\n<figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"768\" src=\"https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2024\/02\/ESR1-1024x768.png\" alt=\"\" class=\"wp-image-3174\" srcset=\"https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2024\/02\/ESR1-1024x768.png 1024w, https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2024\/02\/ESR1-300x225.png 300w, https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2024\/02\/ESR1-768x576.png 768w, https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2024\/02\/ESR1-1536x1152.png 1536w, https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2024\/02\/ESR1.png 1890w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p><strong>A new era for women treated for advanced breast cancer<\/strong><\/p>\n\n\n\n<p>Patients with advanced ER+\/HER2- breast cancer treated with endocrine therapy are at greater risk of developing resistance mutations in various genes, including <strong>Estrogen Receptor 1 (ESR1)<\/strong>.\r\nESR1 mutations, which affect 40% of women in this population, have been identified as a predictive biomarker of tumour response to the most recent treatment protocols using Elacestrant\u00ae.<\/p>\n\n\n\n<p>In line with ESMO, NCCN and ASCO recommendations, ctDNA liquid biopsy is the sample of choice for the <strong>detection of ESR1 mutation status.<\/strong><\/p>\n\n\n\n<p>The monitoring of ESR1 mutations by #dPCR is now recognised as an effective means of enabling patients to be supported by appropriate therapy and for healthcare professionals to address treatment modification when necessary.<\/p>\n\n\n\n<p>ID SOLUTIONS is at your service to provide innovative and valuable solutions for your patients!<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><strong><u>References :<\/u><\/strong>\r\nSpoerke JM et al, Nat Commun 2016 13 :7 :11579\r\nBidard et al. J Clin Oncol 2022 Oct 1 ;40(28) :3246-3256\r\nLone SN et al. Mol Cancer 2022 ;21(1) :79\r\nPascual J et al. Ann. Oncol. 2022, 33 :750-768\r\nDirectives NCCN version 2, 2023 Cancer du sein<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Patients with advanced ER+\/HER2- breast cancer treated with endocrine therapy are at greater risk of developing resistance mutations in various genes, including Estrogen Receptor 1 (ESR1).<\/p>\n","protected":false},"author":2,"featured_media":4638,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","footnotes":""},"categories":[75],"tags":[],"class_list":["post-5184","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-lancement-de-produit-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Liquid biopsy follow-up | ID SOLUTIONS<\/title>\n<meta name=\"description\" content=\"Discover how liquid biopsy and ctDNA monitoring revolutionize treatment for women with advanced ER+\/HER2- breast cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.id-solutions.fr\/en\/2024\/04\/09\/liquid-biopsy-follow-up-a-new-era-for-women-treated-for-advanced-breast-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Liquid biopsy follow-up | ID SOLUTIONS\" \/>\n<meta property=\"og:description\" content=\"Discover how liquid biopsy and ctDNA monitoring revolutionize treatment for women with advanced ER+\/HER2- breast cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.id-solutions.fr\/en\/2024\/04\/09\/liquid-biopsy-follow-up-a-new-era-for-women-treated-for-advanced-breast-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"ID SOLUTIONS\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-09T11:46:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-29T08:09:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2023\/02\/ESR1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1890\" \/>\n\t<meta property=\"og:image:height\" content=\"1417\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"estelle\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"estelle\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Liquid biopsy follow-up | ID SOLUTIONS","description":"Discover how liquid biopsy and ctDNA monitoring revolutionize treatment for women with advanced ER+\/HER2- breast cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.id-solutions.fr\/en\/2024\/04\/09\/liquid-biopsy-follow-up-a-new-era-for-women-treated-for-advanced-breast-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Liquid biopsy follow-up | ID SOLUTIONS","og_description":"Discover how liquid biopsy and ctDNA monitoring revolutionize treatment for women with advanced ER+\/HER2- breast cancer.","og_url":"https:\/\/www.id-solutions.fr\/en\/2024\/04\/09\/liquid-biopsy-follow-up-a-new-era-for-women-treated-for-advanced-breast-cancer\/","og_site_name":"ID SOLUTIONS","article_published_time":"2024-04-09T11:46:32+00:00","article_modified_time":"2024-11-29T08:09:18+00:00","og_image":[{"width":1890,"height":1417,"url":"https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2023\/02\/ESR1.png","type":"image\/png"}],"author":"estelle","twitter_card":"summary_large_image","twitter_misc":{"Written by":"estelle","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.id-solutions.fr\/en\/2024\/04\/09\/liquid-biopsy-follow-up-a-new-era-for-women-treated-for-advanced-breast-cancer\/#article","isPartOf":{"@id":"https:\/\/www.id-solutions.fr\/en\/2024\/04\/09\/liquid-biopsy-follow-up-a-new-era-for-women-treated-for-advanced-breast-cancer\/"},"author":{"name":"estelle","@id":"https:\/\/www.id-solutions.fr\/en\/#\/schema\/person\/d644fb1de25204a236114322bc7f59c6"},"headline":"Liquid biopsy follow-up","datePublished":"2024-04-09T11:46:32+00:00","dateModified":"2024-11-29T08:09:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.id-solutions.fr\/en\/2024\/04\/09\/liquid-biopsy-follow-up-a-new-era-for-women-treated-for-advanced-breast-cancer\/"},"wordCount":172,"publisher":{"@id":"https:\/\/www.id-solutions.fr\/en\/#organization"},"image":{"@id":"https:\/\/www.id-solutions.fr\/en\/2024\/04\/09\/liquid-biopsy-follow-up-a-new-era-for-women-treated-for-advanced-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2023\/02\/ESR1.png","articleSection":["Lancement de produit"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.id-solutions.fr\/en\/2024\/04\/09\/liquid-biopsy-follow-up-a-new-era-for-women-treated-for-advanced-breast-cancer\/","url":"https:\/\/www.id-solutions.fr\/en\/2024\/04\/09\/liquid-biopsy-follow-up-a-new-era-for-women-treated-for-advanced-breast-cancer\/","name":"Liquid biopsy follow-up | ID SOLUTIONS","isPartOf":{"@id":"https:\/\/www.id-solutions.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.id-solutions.fr\/en\/2024\/04\/09\/liquid-biopsy-follow-up-a-new-era-for-women-treated-for-advanced-breast-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.id-solutions.fr\/en\/2024\/04\/09\/liquid-biopsy-follow-up-a-new-era-for-women-treated-for-advanced-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2023\/02\/ESR1.png","datePublished":"2024-04-09T11:46:32+00:00","dateModified":"2024-11-29T08:09:18+00:00","description":"Discover how liquid biopsy and ctDNA monitoring revolutionize treatment for women with advanced ER+\/HER2- breast cancer.","breadcrumb":{"@id":"https:\/\/www.id-solutions.fr\/en\/2024\/04\/09\/liquid-biopsy-follow-up-a-new-era-for-women-treated-for-advanced-breast-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.id-solutions.fr\/en\/2024\/04\/09\/liquid-biopsy-follow-up-a-new-era-for-women-treated-for-advanced-breast-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.id-solutions.fr\/en\/2024\/04\/09\/liquid-biopsy-follow-up-a-new-era-for-women-treated-for-advanced-breast-cancer\/#primaryimage","url":"https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2023\/02\/ESR1.png","contentUrl":"https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2023\/02\/ESR1.png","width":1890,"height":1417},{"@type":"BreadcrumbList","@id":"https:\/\/www.id-solutions.fr\/en\/2024\/04\/09\/liquid-biopsy-follow-up-a-new-era-for-women-treated-for-advanced-breast-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.id-solutions.fr\/en\/home\/"},{"@type":"ListItem","position":2,"name":"Liquid biopsy follow-up"}]},{"@type":"WebSite","@id":"https:\/\/www.id-solutions.fr\/en\/#website","url":"https:\/\/www.id-solutions.fr\/en\/","name":"ID SOLUTIONS","description":"Le diagnostic de pr\u00e9cision au c\u0153ur de notre ADN","publisher":{"@id":"https:\/\/www.id-solutions.fr\/en\/#organization"},"alternateName":"ID SOLUTIONS","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.id-solutions.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.id-solutions.fr\/en\/#organization","name":"ID SOLUTIONS","alternateName":"ID SOLUTIONS","url":"https:\/\/www.id-solutions.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.id-solutions.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2025\/01\/logo-ids.png","contentUrl":"https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2025\/01\/logo-ids.png","width":423,"height":369,"caption":"ID SOLUTIONS"},"image":{"@id":"https:\/\/www.id-solutions.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/id-solutions-diagnostic"]},{"@type":"Person","@id":"https:\/\/www.id-solutions.fr\/en\/#\/schema\/person\/d644fb1de25204a236114322bc7f59c6","name":"estelle","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/69e15dcba3d49c78056721b1e5b1e611520251f42b9bd4504f6619dd71f954cf?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/69e15dcba3d49c78056721b1e5b1e611520251f42b9bd4504f6619dd71f954cf?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/69e15dcba3d49c78056721b1e5b1e611520251f42b9bd4504f6619dd71f954cf?s=96&d=mm&r=g","caption":"estelle"}}]}},"_links":{"self":[{"href":"https:\/\/www.id-solutions.fr\/en\/wp-json\/wp\/v2\/posts\/5184","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.id-solutions.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.id-solutions.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.id-solutions.fr\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.id-solutions.fr\/en\/wp-json\/wp\/v2\/comments?post=5184"}],"version-history":[{"count":2,"href":"https:\/\/www.id-solutions.fr\/en\/wp-json\/wp\/v2\/posts\/5184\/revisions"}],"predecessor-version":[{"id":8741,"href":"https:\/\/www.id-solutions.fr\/en\/wp-json\/wp\/v2\/posts\/5184\/revisions\/8741"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.id-solutions.fr\/en\/wp-json\/wp\/v2\/media\/4638"}],"wp:attachment":[{"href":"https:\/\/www.id-solutions.fr\/en\/wp-json\/wp\/v2\/media?parent=5184"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.id-solutions.fr\/en\/wp-json\/wp\/v2\/categories?post=5184"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.id-solutions.fr\/en\/wp-json\/wp\/v2\/tags?post=5184"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}